We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | 장 마감 후 (AMC) | $-0.52 | — | — | $15.55M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.53 | — | — | $12.35M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-2.25 | — | — | $35.95M |
Consensus PT $11.17 · 6 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 04. 15. | Canaccord Genuity | — | 의견 유지 | Buy → Buy | — | Canaccord Genuity: Buy |
| 2026. 02. 14. | Canaccord Genuity | — | 의견 유지 | Buy → Buy | — | Canaccord Genuity: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| 보고됨 |
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-1.69 | — | — | $22.58M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 114,167 | $1.08B | 0.00% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 24,456 | $173.64M | 0.00% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Stored first · Google News · Yahoo Finance (English)
CVRx to present at Goldman Sachs Healthcare Con... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
CVRx to present at Goldman Sachs Healthcare Con... | Pluang – Crypto, Stocks, Gold & Funds Pluang
CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - GlobeNewswire
CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference GlobeNewswire
CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
CVRX News | CVRX INC (NASDAQ:CVRX) - ChartMill
CVRX News | CVRX INC (NASDAQ:CVRX) ChartMill
Understanding Momentum Shifts in (CVRX) - Stock Traders Daily
Understanding Momentum Shifts in (CVRX) Stock Traders Daily
CVRx stock up on Humana's Medicare coverage for Barostim therapy - MSN
CVRx stock up on Humana's Medicare coverage for Barostim therapy MSN